# Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg

> **NCT03097211** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 38 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** BIA 6-512
- **DRUG:** Madopar® 250
- **DRUG:** Nebicapone

## Key facts

- **NCT ID:** NCT03097211
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-17
- **Primary completion:** 2006-10-20
- **Final completion:** 2006-10-20
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03097211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03097211, "Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03097211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*